Three Years After CARMENA: What Have We Learned?
editorial · Level V
Where this comes from
- Record sourced from PubMed, PMID 34325948.
- Also identified by DOI 10.1016/j.eururo.2021.07.007.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
Cytoreductive nephrectomy makes way for more effective systemic treatments in the current mRCC treatment paradigm, as disease volume and the number of IMDC risk factors increase. Careful patient selection for upfront or deferred cytoreductive nephrectomy based on these criteria remains key.
Medical subject headings
- Carcinoma, Renal Cell
- Kidney Neoplasms